Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Evaxion Biotech A/S ADR (EVAX)

Evaxion Biotech A/S ADR (EVAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,740
  • Shares Outstanding, K 5,866
  • Annual Sales, $ 70 K
  • Annual Income, $ -22,130 K
  • EBIT $ -15 M
  • EBITDA $ -14 M
  • 60-Month Beta -0.24
  • Price/Sales 110.09
  • Price/Cash Flow N/A
  • Price/Book 103.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.03
  • Number of Estimates 1
  • High Estimate -0.03
  • Low Estimate -0.03
  • Prior Year -0.16
  • Growth Rate Est. (year over year) +81.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2800 +16.41%
on 11/20/24
3.1000 -51.94%
on 10/29/24
-1.0700 (-41.80%)
since 10/22/24
3-Month
1.2800 +16.41%
on 11/20/24
3.5500 -58.03%
on 09/10/24
-1.5600 (-51.15%)
since 08/22/24
52-Week
1.2800 +16.41%
on 11/20/24
13.6100 -89.05%
on 01/24/24
-6.5100 (-81.38%)
since 11/22/23

Most Recent Stories

More News
Stock Index Futures Mixed on Pressure from Rising Bond Yields, Oil Prices Rise After Saudi Output Cuts

June S&P 500 futures (ESM23) are up +0.01%, and June Nasdaq 100 E-Mini futures (NQM23) are down -0.25% this morning as market participants digested the U.S. debt ceiling agreement, while U.S. Treasury...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
LULU : 317.11 (+0.63%)
MMM : 128.42 (+0.86%)
AMZN : 197.12 (-0.64%)
VOLCB.S.DX : 23.390 (+2.45%)
MRO : 28.55 (-1.28%)
DVN : 39.45 (+1.94%)
OXY : 51.93 (+0.76%)
DBRG : 12.33 (+3.01%)
RAIN : 1.2100 (-1.63%)
EVAX : 1.4900 (+8.76%)
Evaxion Biotech Announces Second Quarter 2022 Financial Results and Provides Business Update

Expanded DNA oncology vaccine program into non-small cell lung cancer, NSCLCAnnounced successful production of personalized cancer immunotherapies for...

EVAX : 1.4900 (+8.76%)
Evaxion Biotech to Host Q2 2022 Corporate Update Conference Call & Webcast on August 10

COPENHAGEN, Denmark, July 29, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology...

EVAX : 1.4900 (+8.76%)
Evaxion Biotech Announces Gonorrhea as Second Bacterial Product Target

COPENHAGEN, Denmark, June 30, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology...

EVAX : 1.4900 (+8.76%)
Evaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung Cancer

COPENHAGEN, Denmark, June 23, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology...

EVAX : 1.4900 (+8.76%)
Evaxion Biotech Secures Equity Financing of up to $40 Million from Lincoln Park Capital

COPENHAGEN, Denmark, June 07, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology...

EVAX : 1.4900 (+8.76%)
Evaxion Biotech Announces First Quarter 2022 Financial Results and Provides Business Update

Received regulatory clearance in Australia to initiate phase 2b trial of lead cancer therapy EVX-01 targeting melanomaCompleted recruitment for Phase 1/2a...

EVAX : 1.4900 (+8.76%)
Evaxion Biotech to Host Q1 2022 Corporate Update Conference Call & Webcast on May 11

COPENHAGEN, Denmark, April 29, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology...

EVAX : 1.4900 (+8.76%)
Evaxion to Utilize Personalis’ ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage Melanoma

Evaxion Biotech A/S (Nasdaq: EVAX) and Personalis (Nasdaq: PSNL) announced today that Evaxion will deploy Personalis’ ImmunoID NeXT Platform in a Phase 2b trial to evaluate the efficacy and safety of...

EVAX : 1.4900 (+8.76%)
PSNL : 3.47 (+2.66%)
Evaxion Biotech Hosting Key Opinion Leader Webinar on Metastatic Melanoma and Personalized Cancer Immunotherapies

Tuesday, April 12th @ 12:30 pm ET COPENHAGEN, Denmark, April 06, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the...

EVAX : 1.4900 (+8.76%)

Business Summary

Evaxion Biotech A/S is a clinical-stage biotechnology company. It involved in the development of AI-driven immunotherapies for patients with cancer and infectious diseases. Evaxion Biotech A/S is based in COPENHAGEN, Denmark.

See More

Key Turning Points

3rd Resistance Point 1.6583
2nd Resistance Point 1.5741
1st Resistance Point 1.5321
Last Price 1.4900
1st Support Level 1.4059
2nd Support Level 1.3217
3rd Support Level 1.2797

See More

52-Week High 13.6100
Fibonacci 61.8% 8.8999
Fibonacci 50% 7.4450
Fibonacci 38.2% 5.9901
Last Price 1.4900
52-Week Low 1.2800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar